CD80 aAPC CHO-K1 Cell Line

Description

PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells, playing a crucial role in regulating immune responses to tumors and self-antigens. The interaction of PD-1 on neighboring cells with its ligands PD-L1 or PD-L2 inhibits the transmission of TCR signaling pathways, as well as TCR-mediated cell proliferation, transcription activation, and cytokine production effects. Therapeutic antibodies and Fc fusion proteins targeting PD-1/PD-L1 interactions have shown promising applications in clinical trials for treating various cancers.CTLA-4, also known as CD152, is an immune inhibitory receptor expressed constitutively on regulatory T cells (Tregs), playing a key role in regulating immune responses. When CTLA-4 expression on T cell surfaces is upregulated, T cells bind with higher affinity to CD80 (B7-1) or CD86 (B7-2) than CD28’s positive co-stimulatory signal, inducing T cell unresponsiveness. Research has indicated that antibodies and Fc fusion proteins blocking CTLA-4/CD80 and CD86 interactions have shown good prospects in clinical trials for treating a variety of cancers.Clinical data has shown that the combined use of CTLA-4 and PD-1 antibodies, or the use of CTLA-4/PD-1 bispecific antibodies, has better treatment outcomes compared to using single CTLA-4 or PD-1 antibodies.The CTLA4 PD-1 Reporter Cell Line is a stable cell line expressing CTLA-4 and PD-1 luciferase reporter genes. When co-cultured with CD80 PDL1 aAPC CHO-K1 Cell Line, it inhibits TCR downstream signaling in the presence of CTLA-4 blocking CD28 from binding with CD80 and PD-1/PD-L1 interactions. Following the addition of CTLA-4, PD-1, or CTLA-4/PD-1 bispecific antibodies, blocking CTLA-4/PD-1 restores TCR signaling, and the Luciferase readout reflects the activation effect of the signaling pathway. This cell line can be used for in vitro evaluation of CTLA-4/PD-1-related drugs.